Trial · NCT00281879
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879, Phase 2, Terminated, OHSU Knight Cancer Institute; results first posted 2012-06-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer. Trials, record NCT00281879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00281879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
- NCT number
- NCT00281879
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 200 participants, actual
- Lead sponsor
- OHSU Knight Cancer Institute
- Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
- Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- First posted
- 2006-01-25
- Last updated
- 2017-09-27
- Results first posted
- 2012-06-19
- Limitations and caveats
- Early termination
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Disease Free Survival (DFS). | Duration of the study; Up to 2 years | Determine the effectiveness of unrelated donor allogeneic hematopoietic stem cells for transplantation after conditioning for the treatment of high-risk hematopoietic malignancies. Disease-free survival: The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Disease Free Survival (DFS). | Duration of the study; Up to 2 years |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 128 | |
| Overall Study | STARTED | Busulfan and Cyclophosphamide (Cytoxan) | 36 | |
| Overall Study | STARTED | BEAM Regimen | 20 | |
| Overall Study | STARTED | Low-Dose Fludarabine and TBI(for Second Stem Cell Donation) | 0 | |
| Overall Study | STARTED | Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only) | 6 | |
| Overall Study | STARTED | ATG For Cord Blood Transplants | 9 | |
| Overall Study | STARTED | DLI (Donor Leukocyte Infusion) | 0 | |
| Overall Study | STARTED | Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only) | 1 | |
| Overall Study | COMPLETED | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 0 | |
| Overall Study | COMPLETED | Busulfan and Cyclophosphamide (Cytoxan) | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events312
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | General disorders | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 8 | 128 | |
| other | Headache | General disorders | Busulfan and Cyclophosphamide (Cytoxan) | 0 | 36 | |
| other | Headache | General disorders | BEAM Regimen | 2 | 20 | |
| other | Headache | General disorders | Low-Dose Fludarabine and TBI(for Second Stem Cell Donation) | 0 | 0 | 0 |
| other | Headache | General disorders | Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only) | 0 | 6 | 0 |
| other | Headache | General disorders | ATG For Cord Blood Transplants | 0 | 9 | 0 |
| other | Headache | General disorders | DLI (Donor Leukocyte Infusion) | 0 | 0 | 0 |
| other | Headache | General disorders | Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only) | 0 | 1 | 0 |
| other | Nausea | General disorders | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 11 | 128 | |
| other | Nausea | General disorders | Busulfan and Cyclophosphamide (Cytoxan) | 0 | 36 |
1 to 10 of 312Source ClinicalTrials.gov
See all 312 adverse eventsAdverse event totals24
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | ||
| Total, all-cause mortality | Busulfan and Cyclophosphamide (Cytoxan) | ||
| Total, all-cause mortality | BEAM Regimen | ||
| Total, all-cause mortality | Low-Dose Fludarabine and TBI(for Second Stem Cell Donation) | ||
| Total, all-cause mortality | Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only) | ||
| Total, all-cause mortality | ATG For Cord Blood Transplants | ||
| Total, all-cause mortality | DLI (Donor Leukocyte Infusion) | ||
| Total, all-cause mortality | Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only) | ||
| Total, other adverse events | Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 19 | 128 |
| Total, other adverse events | Busulfan and Cyclophosphamide (Cytoxan) | 0 | 36 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016058 | Cancer Center Support Grant | RATHMELL, WENDY KIMRYN | OHIO STATE UNIVERSITY | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00281879
GET https://conductscience.org/api/trials/v1/NCT00281879/flow?page=2